Postconceptional prostaglandin therapy.
392 cases of prostaglandin abortions were analyzed for efficacy, clinical acceptability and complications. It was repeatedly emphasised that the clinical administration of PGs are not without risks and serious drawbacks. The vaginal suppositories seem to be vary promising. It is suggested that new lines of research should be pursued in order to improve our understanding of the effect of PGs and to develop better dose schedules as demanded by clinical and professional excellence.
D000028:Abortion, Induced; D000650:Amnion; D005260:Female; D005313:Fetal Death; D006801:Humans; D011247:Pregnancy; D011453:Prostaglandins / Q000627:therapeutic use*; D011460:Prostaglandins F / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D011453:Prostaglandins; D011460:Prostaglandins F